Among hematological diseases, hemophilias have been successful targets for gene therapy to correct the mutated factor VIII (FVIII) [207] and factor IX (FIX) [208] genes causing hemophilia A and B, respectively (Table 3). This evidence concerns the gene F8 and hemophilia A.